Introduction (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone in patients with polycystic ovarian disease
Several therapeutic approaches have been applied to polycystic (PCOD) and related hyperandrogenisms, in order to evaluovarian disease (PCOD) patients, including diet (Guzick et al. , ate whether the addition of GnRH-a has any advantage. A 1994) and pharmacological agents. As the treatment goal, total of 12 PCOD patients were treated with the EE-CPA especially for related hirsutism, is a reduction in the production, pill alone for 10 consecutive cycles according to an OC bioavailability or binding of the androgens to their target standard regimen. A further 12 patients were treated with organs, the traditional treatment has been the combination of GnRH-a, one i.m. injection every 28 days for a total of oral contraceptives (OC) and anti-androgens, such as eight injections, combined with the EE-CPA pill for 10 cyproterone acetate (CPA). The results of OC treatments have consecutive cycles. The latter was thus prolonged for two often been disappointing, not only because of the incomplete cycles more than GnRH-a. Clinical evaluations (symptoms, suppression of ovarian function, but also because the progestin weight, Ferriman-Gallwey score) and hormonal and biocomponent of most OC pills is derived from 19-nor-testosterone chemical analyses were assessed before, during (at 3 or 6 and therefore has some androgenic activity (Morcos et al., months) and after treatment, either when spontaneous 1994). CPA has also been reported to be effective alone, cycles had resumed or after 3 months of amenorrhoea. associated with OC pills or in combination with oestrogens as There was a significant improvement in hirsutism, and a an OC pill (Belisle and Love, 1986; Galbignani, strong reduction in gonadotrophin, oestradiol, testosterone, 1990; Neumann, 1994) . This combination [CPA ϩ oestrogens androstenedione and 17-OH-progesterone concentrations (EE)] can simultaneously decrease androgen production and in both treatment groups but with no significant differences block androgen action, and it appears to be especially suited between them, except in the gonadotrophin concentrations.
to the treatment of hirsutism, acne or both (Barbieri, 1992 ; Cortisol and triglyceride concentrations increased during Neumann, 1994) . Spirolactone has also been used in the treatment in both groups. The Ferriman-Gallwey score treatment of hirsutism with adequate results but with a significremained significantly decreased in both groups after treatant incidence of dysfunctional uterine bleeding (Helfer et al. , ment, as did androstenedione in the GnRH-a plus EE-CPA 1988). Subsequently, flutamide was shown to be even more pill group, but there were no significant differences between effective (Marcondes et al., 1992; Cusan et al., 1994 ; Moghetti the two groups. No changes were observed in prolactin Pucci et al., 1995) , but because of its potential dehydroepiandrosterone sulphate (DHEA-S), insulin, hepatotoxicity, it requires constant surveillance of liver function glycaemia and cholesterol concentrations. However, when (Wysowski and Fourcroy, 1994; Moghetti et al., 1995) . Finally, only the obese and more hirsute patients were considered, it has been reported that finasteride is useful in idiopathic significant differences between the two groups were found hirsutism (Ciotta et al., 1995) , and ketoconazole in PCOD during treatment in the Ferriman-Gallwey score and the patients (Gökmen et al., 1996) . gonadotrophin and DHEA-S concentrations (which In recent years, gonadotrophin-releasing hormone agonistic increased during treatment in obese patients with the pill analogues (GnRH-a) have been introduced for the evaluation alone), and after treatment in the Ferriman-Gallwey score and treatment of PCOD patients. These produce a state of complete, yet reversible, suppression of pituitary gonadotrophin and the concentration of 17-OH-progesterone in the more examination was performed. Hirsutism was assessed by a global secretion. This results in the suppression of both ovarian scoring system (Ferriman and Gallwey, 1961) , in which a single functions, namely ovulation and steroidogenesis. Hence, in observer (P.A.) assessed hair growth in 11 body areas on a scale of cases of ovarian hyperandrogenism, GnRH-a has been reported 0-4. Height, weight, body mass index (calculated as weight in to be of great benefit Andreyko et al., kg/m 2 ) and percentage of the ideal body weight (IBW; calculated 1986; Steingold et al., 1987; Falsetti and Pasinetti, 1994 ; Goni using the Association of Life Insurance Directors and Actuarial et al., 1994; Morcos et al., 1994) . Long-acting GnRH-a can Society of America tables) were also assessed. be used alone , although this causes hypo-A transvaginal ovarian ultrasonography was performed. Each oestrogenic-related symptoms and decreases bone mineral patient was then allocated one of the two treatment protocols: (i) an content, or in combination with an oestrogen and progestin OC pill containing 0.035 mg EE and 2 mg CPA (Diane 35; replacement therapy (Morcos et al., 1994) , with either standard Schering España SA, Madrid, Spain), from the beginning of the next spontaneous or progesterone-induced cycle, administered for 10 OC pills (Carr et al., 1995; Elkind-Hirsch et al., 1995) Ciotta et al., 1996) .
D-Trp-6-luteinizing hormone-releasing hormone microcapsules (DecaThe aim of this study was to compare the clinical and peptyl 3.75; Lasa Laboratories, Barcelona, Spain), every 28 days, hormonal effects of the combination of a long-acting GnRH-a from day 1 of the next spontaneous or induced cycle, and sometimes plus OC pills containing EE and CPA, versus OC pills alone during the second half of the studied cycle, up to a total of eight in PCOD patients so as to evaluate whether the addition of a injections. In combination with Decapeptyl 3.75, the same OC pill GnRH-a is advantageous and, if so, in which situations.
containing EE and CPA (Diane 35) was administered from day 5 of the cycle for 10 consecutive cycles according to an OC standard regimen, thus prolonging administration of the pill for two cycles
Materials and methods
more than GnRH-a (GnRH-a plus pill group). Subsequently, patients were asked to attend the Gynecological Endocrine Clinic at triSubjects monthly intervals for clinical evaluation (hirsutism, weight, hypo-A total of 24 patients with an average age of 23.2 years (range 14-oestrogenic-related symptoms, psychological status, etc.). Hormonal 32), diagnosed as having PCOD with hirsutism (96%), amenorrhoea and biochemical screenings were repeated randomly at 3 or 6 months or oligomenorrhoea (92%), obesity (61%), seborrhoea (37%) or acne of treatment, and also after the second spontaneous menstruation or (17%), were included in this study. A further five patients were at 3 months of amenorrhoea after withdrawing the treatment. In all, included initially, but later excluded because of the absence of 12 patients were treated with the pill Diane 35 alone for 10 months information in the third and sixth months of treatment. The diagnosis of (pill only group). Five of them had hormonal screening repeated PCOD was established from the patient's clinical history, examination, during the third or fourth cycle of treatment, while the remaining relevant laboratory investigations [including elevated concentrations seven were checked during the sixth or seventh cycle. Another 12 of serum androgens and an increased luteinizing hormone (LH)/ patients were treated with the long-acting GnRH-a, Decapeptyl 3.75, follicle stimulating hormone (FSH) ratio] and ovarian transvaginal plus the Diane 35 pill (GnRH-a plus pill group). Six underwent ultrasonographic criteria (Adams et al., 1986; Takahashi et al., 1994) , further hormonal screening during the third or fourth cycle of including the presence of multiple (ജ10), small (2-8 mm) peripheral treatment, and the remaining six during the sixth or seventh cycle. follicles bilaterally, without dominance, around a dense core of There were no significant differences in the values obtained at these stroma. Diagnosis was also based on the exclusion of other PCODtime points, such that all values were classed together as 'during like syndromes, including adrenal dysfunction, Cushing's syndrome, treatment'. Only nine patients from the pill only group and 10 from congenital adrenal hyperplasia, androgen-producing tumours and the GnRH-a plus pill group returned for their clinical evaluation thyroid dysfunction. General biochemistry (including lipid concentraand hormonal and biochemical analyses in the third month after tions) and concentrations of serum gonadotrophin, prolactin, insulin withdrawing from treatment. The remaining patients from each group and ovarian, thyroid and adrenal hormones were assessed in all decided to continue taking the pill as a contraceptive method without patients. An adrenocorticotrophic hormone stimulation test (New interruption. et al., 1983) and an insulin resistance test to 100 g oral glucose load were performed in all patients. Other inclusion criteria were no other Assays treatment for their disease in the past 3 months, no desire for Before, during and after treatment, hormonal screening for FSH, pregnancy and the absence of other systemic diseases.
LH, prolactin, oestradiol, cortisol, 17-OH-progesterone, testosterone, Study design androstenedione, DHEA-S and insulin was carried out. Glycaemia, cholesterol, high density lipoproteins (HDL)-cholesterol and triglycerAfter the initial diagnosis of PCOD by clinical, hormonal and ides were also assessed. FSH, LH and prolactin concentrations were echographic methods, the included patients were re-evaluated either measured by an immunoenzymatic asssay (MEIA; Abbot); oestradiol on days 5-10 of the menstrual cycle or at any time if they were and testosterone by a double-antibody radioimmunoassay (ICN amenorrhoeic or during a period of anovulation as documented by Biomedicals Inc., Costa Mesa, CA, USA); ∆-4-androstenedione by a plasma progesterone concentrations. They were asked to fast and solid-phase radioimmunoassay (Coat-a-Count; Diagnostic Products abstain from smoking for the 12 h preceding the evaluation. A vein Corporation, Los Angeles, CA, USA); and insulin by a doublecatheter was inserted into an antecubital vein, and after 10 min of antibody radioimmunoassay (Pharmacia, Uppsala, Sweden) using rest, a blood sample was obtained for haematological and biochemical commercially available kits. analysis, including basal gonadotrophin, prolactin, oestradiol, progesterone, 17-OH-progesterone, cortisol, dehydroepiandrosterone Basal parameters sulphate (DHEA-S), testosterone, androstenedione and insulin concentrations. More recently, sex hormone-binding globulin and free
The basal clinical, hormonal and biochemical parameters of the PCOD patients included in each treatment group are shown in Table  testosterone indices were included. Additionally, a complete clinical I. There were no significant differences in any clinical or hormonal treatment, being represented in each figure as the mean of these percentages. Likewise, the unpaired t-test was applied between these parameters between the two groups; however, the patients in the GnRH-a plus EE-CPA pill group were slightly more obese, hirsute 'during' and 'after' percentages for both treatment groups. Differences were considered to be statistically significant if P Ͻ 0.05 but, given and insulin-resistant, with the corresponding hormonal parameters slightly more altered compared with the EE-CPA pill alone group.
that there were few patients in each treatment group, the possibility of a type II error is acknowledged.
Statistical analysis
Statistical analyses were performed using a computer statistical package (R-Sigma; Horus Hardware, 1990 Gallwey scores decreased significantly with both treatments as means Ϯ SD. To compare percentages of subjective improvement, (P Ͻ 0.001), and remained low after treatment with no the Mann-Whitney U-test was used. The pretreatment value of each significant differences between the two groups. The subjective parameter in each studied case was taken to be 100%, and the corresponding percentage was applied to the results during and after indices of improvement (seborrhoea, quality of hair, psycho- logical status) were better for the GnRH-a plus EE-CPA pill
The responses of the Ferriman-Gallwey score and hormonal parameters to both treatment protocols are shown in Table II . group than for the pill alone group (91.7 versus 58.3% of 'good' improvement during treatment), but these differences FSH, LH, oestradiol, 17-OH-progesterone, testosterone and androstenedione concentrations decreased significantly and did not reach statistical significance. None of the patients reported hot flushes, vaginal dryness or other hypo-oestrogeniccortisol concentrations increased significantly during treatment in both groups. Triglyceride concentrations in the Diane 35 related symptoms. pill only group also increased significantly during treatment.
only in FSH and LH concentrations during treatment, the percentage of reduction again being higher for those receiving Differences between the concentrations during treatment in the two groups were significant only for FSH and LH, which the GnRH-a plus pill. There were no differences in the remaining parameters between the two treatment groups. were more decreased in the GnRH-a plus pill group. After treatment, differences between parameters and their pretreatDifferences between determinations at 3 or 6 months were also not statistically significant, although some parameters ment values ceased to be significant, except for the androstenedione which remained significantly decreased in the GnRH-a appeared to be slightly lower at 6 months. However, if only those patients with moderate or severe hirsutism were plus pill group, but with no significant difference between the two treatment groups. There were no significant variations considered (Ferriman-Gallwey score ജ12; seven patients during treatment and five after treatment in the pill only group; during or after treatment in either group for prolactin, DHEA-S, insulin, glycaemia, cholesterol or HDL-cholesterol.
10 and nine patients respectively in the GnRH-a plus pill group), the decrease in that score was significantly greater Figure 1 shows the mean percentages of the values for the studied parameter during and after treatment, with respect to during (68.0 versus 79.5%) and after treatment (69.0 versus 87.2%) in the GnRH-a plus pill group than in the Diane 35 the pretreatment values (defined as 100%), separately for both treatment groups. This enables a graphic representation of the pill only group (Figure 2A) . However, there were no significant differences in the hormonal and biochemical parameters, comparative effects of the treatments on the Ferriman-Gallwey score and the hormonal parameters. Although the Ferrimanexcept for gonadotrophins during treatment and for 17-OHprogesterone which increased after the pill alone treatment Gallwey score decreased to a greater extent with GnRH-a plus pill (66.5 versus 72.3%), the differences were not significant.
( Figure 2B ). Similarly, if only those obese patients with an IBW ജ120% There were significant differences between the two groups were considered (Figure 2C and D; five patients during and was administered in combination Morcos et al., 1994; Carr et al., 1995) . Our study also shows after treatment in the pill only group; eight patients during and six after treatment in the GnRH-a plus pill group), the that the addition of a long-acting GnRH-a (Decapeptyl 3.75) to OC pills containing EE and CPA (Diane 35) maintains the differences in the percentages of the values between the two treatment groups were significant during treatment for the expected improvement induced by the GnRH-a, both clinically and hormonally (decreasing LH, 17-OH-progesterone, androFerriman-Gallwey score and the FSH, LH and DHEA-S concentrations, with the GnRH-a plus EE-CPA pill being stenedione and testosterone) but without the other adverse side-effects. However, because this type of regimen is more the more effective treatment. After treatment, this protocol remained effective (decreasing testosterone and androstenecomplicated and expensive than the use of an OC pill alone, the question as to whether the association is justified remains dione), but the differences were not statistically significant. Interestingly, in these obese patients the androstenedione and unanswered. Our study and others (Carr et al., 1995) showed that, in the general group of PCOD patients, the clinical and DHEA-S concentrations increased slightly during treatment with the EE-CPA pill alone.
hormonal differences were not significant. However, when only the obese (IBW Ͼ120%) and/or severely hirsute patients were considered, the differences became significant in favour Discussion of the use of GnRH-a associated with OC EE-CPA pills. Furthermore, plasma DHEA-S concentrations increased during In accordance with previous studies (Belisle and Love, 1986 ), a cyclical prolonged treatment (10 months) with OC pills treatment with OC EE-CPA pills alone in obese patients. On the other hand, cortisol concentrations increased significantly containing EE and CPA (Diane 35) was effective in reducing gonadotrophic and androgen concentrations and improving in both treatment groups. This is in good agreement with the glucocorticoid activity reported for CPA in both humans hirsutism, acne and subjective perceptions (seborrhoea, psychological status and quality of new hair) in PCOD patients. The (Gaspard et al., 1980) and animals (Poyet and Labrie, 1985) , but no symptoms or related side-effects have been observed addition of a long-acting GnRH-a in the form of triptoreline (Decapeptyl 3.75), one i.m. injection every 28 days for in this sense (Belisle and Love, 1986 ).
In conclusion, since a cyclical prolonged treatment with the eight cycles, improved the clinical results slightly (FerrimanGallwey score and subjective perceptions), although the differ-OC EE-CPA pill is effective and has the advantage of the anti-oestrogenic action of CPA on hirsutism, and considering ences were not statistically significant. The only significant difference resulting from the addition of GnRH-a to the OC that the addition of a GnRH-a is more complicated and expensive with no significant improvement in the results, it pill was the greater reduction in gonadotrophins (especially LH) during treatment. After treatment, the Ferriman-Gallwey seems that such an association is not justified in most PCOD patients. However, the addition of the long-acting GnRH-a score and androgen concentrations (testosterone and androstenedione) in the GnRH-a plus pill group remained may be recommended in obese and severely hirsute patients. lower than in the group with OC pill alone, but again the differences were not statistically significant. Carr et al. (1995) and Elkind-Hirsch et al. (1995) observed similar results during
